TY - JOUR
T1 - The association between polluted neighborhoods and TP53-mutated non–small cell lung cancer
AU - Erhunmwunsee, Loretta
AU - Wing, Sam E.
AU - Shen, Jenny
AU - Hu, Hengrui
AU - Sosa, Ernesto
AU - Lopez, Lisa N.
AU - Raquel, Catherine
AU - Sur, Melissa
AU - Ibarra-Noriega, Pilar
AU - Currey, Madeline
AU - Lee, Janet
AU - Kim, Jae Y.
AU - Raz, Dan J.
AU - Amini, Arya
AU - Sampath, Sagus
AU - Koczywas, Marianna
AU - Massarelli, Erminia
AU - West, Howard L.
AU - Reckamp, Karen L.
AU - Kittles, Rick A.
AU - Salgia, Ravi
AU - Seewaldt, Victoria L.
AU - Neuhausen, Susan L.
AU - Gray, Stacy W.
N1 - Funding Information:
L. Erhunmwunsee reports grants from NIH K12 award during the conduct of the study, as well as grants from AstraZeneca Pharmaceuticals outside the submitted work. D.J. Raz reports personal fees from Roche and AstraZeneca outside the submitted work. E. Massarelli reports personal fees from AstraZeneca and Merck outside the submitted work. K.L. Reckamp reports personal fees and non-financial support as a consultant (honoraria to self) from Calithera, Euclises, Guardant, Precision Health, Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, EMD Serono, Genentech, Janssen, Lilly, Merck KGA, Seattle Genetics, Takeda, and Tesaro and grant/research support to institution from AbbVie, Acea, Adaptimmune, Guardant, Molecular Partners, Seattle Genetics, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Loxo Oncology, Spectrum, Takeda, Xcovery, Zeno, Calithera, Daiichi Sankyo, and Elevation Oncology outside the submitted work. S.W. Gray reports personal fees from TripTych Health Partners outside the submitted work. No disclosures were reported by the other authors.
Funding Information:
We thank Kerin Higa, PhD, for reviewing and editing the manuscript. Research reported in this publication was supported by the NCI of the NIH under award number K17CA001727. One hundred percent of the total costs for this publication were by financed a nongovernmental source, for a total of $30,000.00.
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/8
Y1 - 2021/8
N2 - Background: Poor patients often reside in neighborhoods of lower socioeconomic status (SES) with high levels of airborne pollutants. They also have higher mortality from non–small cell lung cancer (NSCLC) than those living in wealthier communities. We investigated whether living in polluted neighborhoods is associated with somatic mutations linked with lower survival rates, i.e., TP53 mutations. Methods: In a retrospective cohort of 478 patients with NSCLC treated at a comprehensive cancer center between 2015 and 2018, we used logistic regression to assess associations between individual demographic and clinical characteristics, including somatic TP53 mutation status and environmental risk factors of annual average particulate matter (PM2.5) levels, and neighborhood SES. Results: 277 patients (58%) had somatic TP53 mutations. Of those, 45% lived in neighborhoods with “moderate” Environmental Protection Agency–defined PM2.5 exposure, compared with 39% of patients without TP53 mutations. We found significant associations between living in neighborhoods with “moderate” versus “good” PM2.5 concentrations and minority population percentage [OR, 1.06; 95% confidence interval (CI), 1.04–1.08]. There was a significant association between presence of TP53 mutations and PM2.5 exposure (moderate versus good: OR, 1.66; 95% CI, 1.02–2.72) after adjusting for patient characteristics, other environmental factors, and neighborhood-level SES. Conclusions: When controlling for individual- and neighborhood-level confounders, we find that the odds of having a TP53-mutated NSCLC are increased in areas with higher PM2.5 exposure. Impact: The link between pollution and aggressive biology may contribute to the increased burden of adverse NSCLC outcomes in individuals living in lower SES neighborhoods.
AB - Background: Poor patients often reside in neighborhoods of lower socioeconomic status (SES) with high levels of airborne pollutants. They also have higher mortality from non–small cell lung cancer (NSCLC) than those living in wealthier communities. We investigated whether living in polluted neighborhoods is associated with somatic mutations linked with lower survival rates, i.e., TP53 mutations. Methods: In a retrospective cohort of 478 patients with NSCLC treated at a comprehensive cancer center between 2015 and 2018, we used logistic regression to assess associations between individual demographic and clinical characteristics, including somatic TP53 mutation status and environmental risk factors of annual average particulate matter (PM2.5) levels, and neighborhood SES. Results: 277 patients (58%) had somatic TP53 mutations. Of those, 45% lived in neighborhoods with “moderate” Environmental Protection Agency–defined PM2.5 exposure, compared with 39% of patients without TP53 mutations. We found significant associations between living in neighborhoods with “moderate” versus “good” PM2.5 concentrations and minority population percentage [OR, 1.06; 95% confidence interval (CI), 1.04–1.08]. There was a significant association between presence of TP53 mutations and PM2.5 exposure (moderate versus good: OR, 1.66; 95% CI, 1.02–2.72) after adjusting for patient characteristics, other environmental factors, and neighborhood-level SES. Conclusions: When controlling for individual- and neighborhood-level confounders, we find that the odds of having a TP53-mutated NSCLC are increased in areas with higher PM2.5 exposure. Impact: The link between pollution and aggressive biology may contribute to the increased burden of adverse NSCLC outcomes in individuals living in lower SES neighborhoods.
UR - http://www.scopus.com/inward/record.url?scp=85111665326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111665326&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-20-1555
DO - 10.1158/1055-9965.EPI-20-1555
M3 - Article
C2 - 34088750
AN - SCOPUS:85111665326
SN - 1055-9965
VL - 30
SP - 1498
EP - 1505
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 8
ER -